Spotlight

Physicians typically address movement disorders, such as tardive dyskinesia, during in-person examinations; however, a recent study shows that telehealth visits can be a part of treatment plans.

Patients with tardive dyskinesia being treated with vesicular monoamine transporter 2 inhibitors may see improvement in well-being along with TD symptoms.

Between 20% and 30% of patients with schizophrenia (SCZ)—and up to 50% patients with SCZ older than 50—develop tardive dyskinesia (TD), according to a study published in Genes & Genomics.

An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.

First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.

Biomarker testing in non-small cell lung cancer informs therapeutic decisions at all stages of...

Comprehensive biomarker testing of patients with non-small lung cancer (NSCLC) is a critical part...

Biomarker testing is crucial for managing non-small cell lung cancer (NSCLC), with plasma-based...

Researchers conducted a study to investigate the experiences of patients and clinicians regarding...

A study aimed to enhance comprehensive biomarker testing for patients with metastatic...

A study aimed to analyze changes in biomarker testing among patients with metastatic non-small...

The following is a summary of “Role of tumor density in predicting significant cancer on targeted...

The following is a summary of “Clinical and treatment characteristics of secondary bladder...

Scientific knowledge of tardive dyskinesia (TD) over the past five decades will prove useful for...